Article Text

Download PDFPDF
No significant difference between olanzapine and placebo for improvement in borderline personality disorder symptoms

Statistics from



What is the efficacy and safety of variable dose olanzapine in people with borderline personality disorder?


314 outpatients (aged 18–65 years) with borderline personality disorder (DSM-IV) and scoring 9 on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) score at randomisation (see online notes for main exclusion criteria).


52 sites in nine countries: Belgium, France, Germany, Norway, Portugal, Spain, Sweden, UK and USA; time period not stated.


Olanzapine (2.5–20 mg/day) or placebo. Participants taking olanzapine started on 2.5 mg or 5 mg/day based on the investigator’s judgement. After 1 week, if needed, doses could be increased or decreased in 2.5 or 5 mg doses to a maximum of 20 mg/day. At week 4, participants without a ⩾30% reduction in the ZAN-BPD score were prescribed incremental dose increases (up to a maximum of 20 mg/day) unless precluded by adverse events. Participants on maximum dose and failing to achieve a reduction in score remained in the study at the investigator’s discretion.


The primary outcome measure was mean change from …

View Full Text


  • Source of funding: Eli Lilly.


  • Competing interests: None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.